ArticleAnnals of medicine and surgery (2012)2026
Survival analysis and prognostic factors for gastrointestinal and extragastrointestinal stromal tumors: a SEER-based study.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Less frequently, these tumors can occur outside of the gastrointestinal tract and are termed extragastrointestinal stromal tumors (EGISTs). GISTs and EGISTs share similar molecular and histopathological characteristics; however, the exact pathogenesis of EGISTs is yet to be understood. In this study, we retrospectively reviewed all GIST cases present in the Surveillance, Epidemiology, and End Results (SEER) database. A total of 18 819 patients were included in this analysis, of which 918 had EGIST. Median overall survival and cancer-specific survival (CSS) were not reached in our study. GIST patients had significantly longer CCS than EGIST patients. EGIST, male, regional disease, distant, non-Hispanic Black, age, and radiotherapy were independently associated with shorter CCS in the general population. Contrarily, surgery was a protective factor. Distant disease, increased age, and radiotherapy were independently associated with poor CCS in EGIST patients. In conclusion, surgery should remain the mainstay of treatment in GIST and EGIST patients. The neoplasm appears to be resistant to radiotherapy, and its side effects may worsen patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.